Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 10, 2016, Pages 2691-2703

  Ghimire, Samiksha ^a   van't Boveneind Vrubleuskaya, Natasha ^a,b   Akkerman, Onno W ^a   de Lange, Wiel C M ^a   van Soolingen, Dick ^c,d   Kosterink, Jos G W ^a,e   van der Werf, Tjip S ^a   Wilffert, Bob ^a,e   Touw, Daniel J ^a   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Metropolitan Public Health Service Haaglanden   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CEREBROSPINAL FLUID; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; RADIOMETRY; RISK FACTOR; SYSTEMATIC REVIEW; ADULT; CHILD; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MICROBIAL SENSITIVITY TEST; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84994718634     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw164     Document Type: Article

References (82)

1. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-83.
2. Wilby KJ, Ensom MH, Marra F. Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults. Clin Pharmacokinet 2014; 53: 873-90.
3. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74: 839-54.
4. WHO. Global Tuberculosis Report. 2015. http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1.
5. Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-43.
6. Lange C, Abubakar I, Alffenaar JW et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63.
7. Blumberg HM, BurmanWJ, Chaisson RE et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
8. Pranger AD, Alffenaar JWC, Aarnoutse RE. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach. Curr Pharm Des 2011; 17: 2900-30.
9. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008; issue 1: CD004795.
10. Falzon D, Gandhi N, Migliori GB et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-68.
11. Orenstein EW, Basu S, Shah NS et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-61.
12. Gumbo T, Louie A, Deziel MR et al. Selection of amoxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-51.
13. van der Paardt A, Wilffert B, Akkerman OWet al. Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. Eur Respir J 2015; 46: 444-55.
14. Alsaad N, Wilffert B, van Altena R et al. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J 2014; 43: 884-97.
15. Zumla AI, Gillespie SH, Hoelscher M et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014; 14: 327-40.
16. Skripconoka V, Danilovits M, Pehme L et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-400.
17. Tiberi S, De Lorenzo S, Centis R et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-92.
18. Van Altena R, de Vries G, Haar C et al. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009. Lancet Infect Dis 2015; 19: 406-12.
19. Srivastava S, Peloquin CA, Sotgiu G et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013; 42: 1449-53.
20. Laniado-Laborin R, Moser K, Estrada-Guzman J et al. Successful treatment of multidrug-resistant tuberculosis through a binational consortium. Eur Respir J 2011; 38 Suppl 55: 398.
21. Aarnoutse RE, Sturkenboom MG, Robijns K et al. An interlaboratory quality control programme for the measurement of tuberculosis drugs. Eur Respir J 2015; 46: 268-71.
22. Cegielski JP, Dalton T, Yagui M et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59: 1049-63.
23. Peloquin C. Use of therapeutic drug monitoring in tuberculosis patients. Chest J 2004; 126: 1722-4.
24. Peloquin CA. Tuberculosis drug serum levels. Clin Infect Dis 2001; 33: 584-5.
25. Kikvidze M, Ikiashvili L. Comorbidities and MDR-TB treatment outcomes in Georgia-2009-11 cohort. Eur Respir J 2014; 44 Suppl 58: P1444.
26. Daskapan A, de Lange WC, Akkerman OWet al. The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. Eur Respir J 2015; 45: 569-71.
27. Akkerman OW, van Altena R, Klinkenberg T et al. Drug concentration in lung tissue in multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 1750-2.
28. Pasipanodya JG, McIlleron H, Burger A et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464-73.
29. Pranger AD, van Altena R, Aarnoutse RE et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38: 888-94.
30. Kang BH, Shim TS, Lee S et al. Current status of fluoroquinolone use for treatment of tuberculosis in Korea. Eur Respir J 2013; 42 Suppl 57: P2822.
31. Malik M, Drlica K. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol. Antimicrob Agents Chemother 2006; 50: 2842-4.
32. Koh W, Lee SH, Kang YA et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Resp Crit Care 2013; 188: 858-64.
33. Alffenaar JC, Gumbo T, Aarnoutse RE. Acquired drug resistance: we can do more than we think! Clin Infect Dis 2015; 60: 969-70.
34. Mor N, Vanderkolk J, Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother 1994; 38: 1161-4.
35. Rodriguez JC, Cebrian L, Lopez M et al. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004; 53: 441-4.
36. Hozo SP, Djulbegovic B, Hozo I. Estimating themean and variance fromthe median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
37. Angeby KA, Jureen P, Giske CG et al. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother 2010; 65: 946-52.
38. Thwaites GE, Bhavnani SM, Chau TTet al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother 2011; 55: 3244-53.
39. Rey-Jurado E, Tudo G, de la Bellacasa JP et al. In vitro effect of threedrug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2013; 41: 278-80.
40. Blackman A, May S, Devasia R et al. Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance. Eur J Clin Microbiol Infect Dis 2012; 31: 2177-82.
41. Rodriguez JC, Ruiz M, Climent A et al. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001; 17: 229-31.
42. Morcillo N, Di Giulio B, Testani B et al. A microplate indicator-based method for determining the susceptibility of multidrug-resistant Mycobacterium tuberculosis to antimicrobial agents. Int J Tuberc Lung Dis 2004; 8: 253-9.
43. Ruiz-Serrano MJ, Alcala L, Martinez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000; 44: 2567-8.
44. Lai CC, Tan CK, Huang YT et al. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a medical center in Taiwan. Clin Infect Dis 2008; 47: e57-63.
45. Singh M, Chauhan DS, Gupta P et al. In vitro effect of fluoroquinolones against Mycobacterium tuberculosis isolates from Agra & Kanpur region of north India. Indian J Med Res 2009; 129: 542-7.
46. Ahmed I, Jabeen K, Inayat R et al. Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate. Antimicrob Agents Chemother 2013; 57: 2522-5.
47. Wang JY, Lee LN, Lai HC et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007; 59: 860-5.
48. Huang TS, Kunin CM, Shin-Jung Lee S et al. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005; 56: 1058-62.
49. Rodriguez JC, Ruiz M, Lopez M et al. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002; 20: 464-7.
50. Perlman DC, El Sadr WM, Heifets LB et al. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. AIDS 1997; 11: 1473-8.
51. Imperiale B, Zumárraga M, Di Giulio A et al. Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to antituberculosis drugs. Int J Tuberc Lung Dis 2013; 17: 1088-93.
52. Mpagama SG, Ndusilo N, Stroup S et al. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2014; 58: 782-8.
53. Johnson J, Hadad D, Boom Wet al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-12.
54. Peloquin CA, Hadad DJ, Molino LP et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852-7.
55. Thee S, Garcia-Prats AJ, McIlleron HM et al. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrugresistant tuberculosis in children. Antimicrob Agents Chemother 2014; 58: 2948-51.
56. Thee S, Garcia-Prats A, Donald P et al. Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis 2015; 95: 229-45.
57. Donald P. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis 2010; 90: 279-92.
58. Mase SR, Jereb JA, Gonzalez D et al. Pharmacokinetics and dosing of levofloxacin in children treated for active or latent multidrug-resistant tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. Pediatr Infect Dis J 2016; 35: 414-21.
59. Chien SC, Wong FA, Fowler CL et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 885-8.
60. Sirgel FA, Warren RM, Streicher EM et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2012; 67: 1088-93.
61. Heysell SK, Ahmed S, Ferdous SS et al. Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice. PLoS One 2015; 10: e0116795.
62. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58: 29-36.
63. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54: 1484-91.
64. Alsultan A, An G, Peloquin CA. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis. Antimicrob Agents Chemother 2015; 59: 3800-7.
65. Bastos ML, Hussain H, Weyer K et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first-and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 2014; 59: 1364-74.
66. Gumbo T, Pasipanodya JG, Wash P et al. Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob Agents Chemother 2014; 58: 6111-5.
67. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy 2001; 47 Suppl 3: 9-14; discussion 44-8.
68. Modai J. High-dose intravenous fluoroquinolones in the treatment of severe infections. J Chemother 1999; 11: 478-85.
69. Senneville E, Poissy J, Legout L et al. Safety of prolonged high-dose levofloxacin therapy for bone infections. J Chemother 2007; 19: 688-93.
70. Alffenaar JW, van Altena R, Bokkerink HJ et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009; 49: 1080-2.
71. Ruslami R, Ganiem A, Dian S et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an openlabel, randomised controlled phase 2 trial. Lancet Infect Dis 2013; 13: 27-35.
72. Chien S, Wells TG, Blumer JL et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol 2005; 45: 153-60.
73. WHO. Implementing Tuberculosis Diagnostics: A Policy Framework. 2015. http://www.who.int/tb/publications/implementing_TB_diagnostics/en/.
74. Hofman S, Bolhuis MS, Koster RA et al. Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. Bioanalysis 2015; 7: 481-95.
75. Ängeby K, Juréen P, Kahlmeter G et al. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 2012; 90: 693-8.
76. WHO. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. 2015. http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf?ua=1&ua=1
77. WHO. World Health Organization Policy Guidance on Drug-susceptibility Testing (DST) of Second-line Antituberculosis Drugs. 2008. http://apps.who. int/iris/bitstream/10665/70500/1/WHO_HTM_TB_2008.392_eng.pdf.
78. Nosova EY, Bukatina AA, Isaeva YD et al. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J Med Microbiol 2013; 62: 108-13.
79. Yin X, Yu Z. Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China. J Infect 2010; 61: 150-4.
80. Lourenço M, Junior IN, De Souza M. In vitro activity of ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and gatifloxacin against multidrugresistant Mycobacterium tuberculosis in Rio de Janeiro Brazil. Med Mal Infect 2007; 37: 295-6.
81. Rodriguez J, Ruiz M, Climent A et al. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001; 17: 229-31.
82. van der Heijden YF, Maruri F, Blackman A et al. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older-versus newer-generation fluoroquinolones. Int J Antimicrob Agents 2013; 42: 232-7.